Large-scale testing (Phase 3)Study completedNCT02404350
What this trial is testing
Study to Demonstrate the Efficacy (Including Inhibition of Structural Damage), Safety and Tolerability up to 2 Years of Secukinumab in Active Psoriatic Arthritis
Who this might be right for
Psoriatic Arthritis
Novartis Pharmaceuticals 997